Myriad Genetics

To advance health and well-being by making genetic insights integral to every major health decision for millions.

Myriad Genetics SWOT Analysis

Updated: October 6, 2025 • 2025-Q4 Analysis

How to Use This Analysis

This analysis for Myriad Genetics was created using Alignment.io™ methodology - a proven strategic planning system trusted in over 75,000 strategic planning projects. We've designed it as a helpful companion for your team's strategic process, leveraging leading AI models to analyze publicly available data.

While this represents what AI sees from public data, you know your company's true reality. That's why we recommend using Alignment.io and The System of Alignment™ to conduct your strategic planning—using these AI-generated insights as inspiration and reference points to blend with your team's invaluable knowledge.

Powered by Leading AI Models

Anthropic

Industry-leading reasoning capabilities with 200K context window for comprehensive analysis

Google Gemini

State-of-the-art multimodal intelligence with real-time market data processing and trend analysis

OpenAI GPT

Advanced reasoning with comprehensive industry knowledge and strategic problem-solving capabilities

This Myriad Genetics SWOT Analysis reveals a company at a critical inflection point. Its core strengths—a diverse portfolio, trusted brand, and invaluable data asset—provide a strong foundation. However, the path to its vision is challenged by persistent unprofitability and intense competitive pricing pressure. The key to victory lies in leveraging its data as a moat, aggressively expanding into the high-growth mental health and international markets, and achieving sustainable profitability through operational excellence. The opportunities in pharma partnerships and deeper EMR integration are accelerators that must be seized. Ignoring the regulatory threats and the commoditizing force of competition would be a fatal error. The strategic imperative is clear: differentiate through innovation and data, expand into new frontiers, and build a profitable, resilient business model capable of funding its long-term vision of preventative, personalized medicine for all.

Natera Invitae Exact Sciences Fulgent Genetics Guardant Health

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To advance health and well-being by making genetic insights integral to every major health decision for millions.

Toggle Theme

Strengths

PORTFOLIO: Diverse product mix shields from single-product risk (16% vol growth)
BRAND: 30+ years of trust with oncologists and OB/GYNs is a key moat
DATA: Massive proprietary genetic database is a major competitive asset
SCALE: Established lab infrastructure allows for efficient test processing
PAYER: Broad in-network coverage with major US health insurance payers

Weaknesses

PROFITABILITY: History of net losses, turnaround still in progress (Q1 loss $4.8M)
PRICING: Intense competitive pressure continues to erode average selling prices
TECH: Legacy systems may slow down integration of new tech and AI models
DEBT: While manageable, debt service impacts cash available for R&D
PERCEPTION: Past controversies over BRCA patents linger in public memory

Opportunities

MENTAL HEALTH: GeneSight market is large and underpenetrated, driving growth
INTERNATIONAL: Significant revenue potential outside the US is untapped
PHARMA: Companion diagnostics partnerships offer high-margin revenue streams
INTEGRATION: Deep EMR integration can create sticky provider relationships
LIQUID BIOPSY: Entering the minimal residual disease (MRD) market is key

Threats

COMPETITION: Aggressive pricing from Natera, Invitae, and others is a major threat
REGULATION: Potential FDA regulation of LDTs could increase compliance costs
REIMBURSEMENT: Payer uncertainty and policy changes are a constant risk
TECHNOLOGY: Rapid technological shifts could make current tests obsolete
PRIVACY: Heightened consumer and regulatory focus on genetic data privacy

Key Priorities

PROFITABILITY: Drive to sustainable profitability through cost discipline & growth
DIFFERENTIATION: Leverage data and brand to defend against price commoditization
EXPANSION: Aggressively pursue growth in mental health and international markets
INNOVATION: Invest in next-gen tech like liquid biopsy and AI applications

Create professional SWOT analyses in minutes with our AI template. Get insights that drive real results.

Get Free SWOT Analysis Template

Myriad Genetics OKR

Updated: October 6, 2025 • 2025-Q4 Analysis

The Myriad Genetics OKR plan is a focused and potent blueprint for execution. It correctly prioritizes achieving sustainable profitability as the bedrock for all future ambitions. The objectives to expand market leadership and unlock the value of data are perfectly aligned with core strengths, while the focus on winning markets directly confronts the primary competitive threats. The key results are specific, measurable, and rightly blend financial discipline with strategic investments in innovation like AI and liquid biopsy. This plan provides the clarity and accountability needed to translate Myriad's turnaround narrative into tangible, market-leading performance and shareholder value. It's a plan for building an enduring, impactful enterprise.

Natera Invitae Exact Sciences Fulgent Genetics Guardant Health

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To advance health and well-being by making genetic insights integral to every major health decision for millions.

ACHIEVE PROFITABILITY

Forge a sustainable, profitable financial future for Myriad.

MARGINS: Improve non-GAAP gross margins from 72% to 75% by optimizing lab workflows and supply costs
OPERATIONS: Reduce SG&A as a percentage of revenue from 65% to 60% through disciplined cost management
CASHFLOW: Generate positive adjusted operating cash flow for four consecutive quarters to fund innovation
AUTOMATION: Decrease manual variant review time by 30% via AI, lowering COGS and speeding results

EXPAND LEADERSHIP

Dominate high-growth markets and solidify our core.

GENESIGHT: Increase GeneSight testing volume by 25% through expanded commercial reach and provider education
WOMEN'S HEALTH: Grow combined Prequel/Foresight market share by 5 points in the carrier screening segment
GLOBAL: Establish a direct commercial presence in two key European markets, generating $10M in new revenue
ONCOLOGY: Secure a top-tier pharma partnership for a companion diagnostic based on our Precise platform

UNLOCK DATA

Transform our data asset into a strategic weapon.

PLATFORM: Complete migration of 75% of historical variant data onto a unified, AI-ready cloud platform
PRODUCT: Launch a new AI-driven polygenic risk score (PRS) offering for hereditary cancer risk assessment
INSIGHTS: Publish two high-impact studies using our dataset to reveal novel gene-disease associations
PARTNER: Initiate a data-as-a-service pilot program with one biopharma partner to validate our dataset

WIN MARKETS

Outmaneuver competitors with superior innovation.

MRD: Advance our liquid biopsy (MRD) product to be ready for clinical validation stage by year-end
INTEGRATION: Launch a new EMR integration application with a major vendor to streamline test ordering
EXPERIENCE: Achieve a 10-point increase in physician Net Promoter Score (NPS) for our ordering portal
EVIDENCE: Fund three new clinical utility studies to strengthen reimbursement cases for key products

METRICS

Adjusted Operating Income: Achieve positive result
Testing Volume Growth: >15% Annually
Revenue: $850M

VALUES

Lead with compassion
Put patients first
Act with integrity
Think big, act fast
Build a better way

Build strategic OKRs that actually work. AI insights meet beautiful design for maximum impact.

Get Free OKR Template

Myriad Genetics Retrospective

AI-Powered Insights

Claude

Gemini

GPT

Myriad Genetics Q1 2024 Earnings Report & Press Release
Myriad Genetics Investor Relations Website (Presentations, SEC Filings)
Reputable financial news sources (e.g., Yahoo Finance, MarketWatch)
Myriad Genetics Official Company Website (myriad.com)
Competitor financial reports and websites for comparative analysis

Natera Invitae Exact Sciences Fulgent Genetics Guardant Health

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To advance health and well-being by making genetic insights integral to every major health decision for millions.

Toggle Theme

What Went Well

VOLUME: Strong testing volume growth of 16% YoY shows robust demand
GENESIGHT: Continued double-digit growth in Mental Health segment
MARGINS: Gross margin improvement reflects pricing and cost discipline
CASHFLOW: Positive adjusted operating cash flow demonstrates progress
REVENUE: Beat consensus revenue estimates, signaling turnaround traction

Not So Well

PROFITABILITY: Still reporting a GAAP net loss, path to profit is key
PRICING: Average selling price (ASP) pressure continues in some areas
ONCOLOGY: Oncology revenue growth was modest compared to other segments
GUIDANCE: Conservative forward guidance may have concerned investors
EXPENSES: R&D and SG&A expenses remain high as a percentage of revenue

Learnings

FOCUS: Laser focus on high-growth areas like GeneSight is paying off
DISCIPLINE: Cost management is critical for achieving sustainable profit
MARKET: The market rewards consistent execution and profitability path
DIVERSIFICATION: A diverse portfolio provides resilience against headwinds
COMMUNICATION: Clearly articulating the long-term strategy is crucial

Action Items

COSTS: Execute on operational efficiency plan to further improve margins
SALES: Double down on commercial execution for GeneSight and Women's Health
R&D: Accelerate pipeline development for liquid biopsy (MRD) products
INTEGRATION: Launch pilot programs for deeper EMR integration this year
CAPITAL: Continue disciplined capital allocation to strengthen balance sheet

Run better retrospectives in minutes. Get insights that improve your team.

Get Free Retro Template

Organization	SWOT Analysis	OKR Plan	Top 6	Retrospective

Explore specialized team insights and strategies

Myriad Genetics Market

AI-Powered Insights

Claude

Gemini

GPT

Myriad Genetics Q1 2024 Earnings Report & Press Release
Myriad Genetics Investor Relations Website (Presentations, SEC Filings)
Reputable financial news sources (e.g., Yahoo Finance, MarketWatch)
Myriad Genetics Official Company Website (myriad.com)
Competitor financial reports and websites for comparative analysis

Founded: 1991, by founders from University of Utah.
Market Share: Leading share in Hereditary Cancer, growing in others.
Customer Base: Physicians (OB/GYNs, oncologists), patients, pharma.
Category:
Genetic Testing
SIC Code: 8071 Medical Laboratories
NAICS Code: 621511 Medical Laboratories
Location: Salt Lake City, Utah
Zip Code: 84108
Congressional District: UT-1 SALT LAKE CITY
Employees: 2800

Competitors

Natera View Analysis

Invitae Request Analysis

Exact Sciences View Analysis

Fulgent Genetics View Analysis

Guardant Health View Analysis

Products & Services

No products or services data available

Distribution Channels

Myriad Genetics Business Model Analysis

AI-Powered Insights

Claude

Gemini

GPT

Myriad Genetics Q1 2024 Earnings Report & Press Release
Myriad Genetics Investor Relations Website (Presentations, SEC Filings)
Reputable financial news sources (e.g., Yahoo Finance, MarketWatch)
Myriad Genetics Official Company Website (myriad.com)
Competitor financial reports and websites for comparative analysis

Problem

One-size-fits-all approach to medicine
Late diagnosis of preventable diseases
Ineffective trial-and-error prescribing

Solution

Actionable genetic tests for personalized care
Early risk identification for cancer/disease
Genetic guidance for medication selection

Key Metrics

Test Volume, Average Selling Price (ASP)
Revenue Growth, Adjusted Operating Income
Customer Acquisition Cost, Gross Margin %

Unique

Largest proprietary human genetic database
30+ year brand trust with clinicians
Superior variant classification engine

Advantage

Vast, clinically annotated dataset
Deeply entrenched commercial relationships
Regulatory and reimbursement expertise

Channels

Direct sales force targeting physicians
Partnerships with major health systems
Digital marketing to patients/providers

Customer Segments

Oncologists, OB/GYNs, Psychiatrists
Patients and their families
Pharmaceutical and biotech companies

Costs

R&D for new test development
Lab operational costs (reagents, labor)
Sales, General & Administrative (SG&A)

Myriad Genetics Product Market Fit Analysis

Updated: October 6, 2025

Myriad Genetics empowers doctors and patients with precise genetic insights to preemptively manage disease and select the most effective treatments. This personalized approach improves patient outcomes, eliminates wasteful spending on ineffective care, and establishes a new, proactive standard in medicine, from oncology to mental health, backed by three decades of scientific leadership and data.

Actionable insights that improve patient outcomes

Personalized care paths reducing healthcare costs

Trusted scientific rigor and clinical support

Before State

Reactive, one-size-fits-all treatments
Uncertainty about hereditary disease risk
Trial-and-error mental health medication

After State

Personalized, targeted therapies chosen
Proactive health plans based on genetics
Informed mental health treatment paths

Negative Impacts

Ineffective treatments and side effects
Delayed diagnosis of critical diseases
Anxiety and wasted healthcare spending

Positive Outcomes

Better patient outcomes and lower costs
Early disease detection and prevention
Faster relief for mental health patients

Key Metrics

Test Volume Growth

16% YoY in Q1 2024

Customer Retention Rates

High with clinicians

Net Promoter Score (NPS)

Estimated 50-60

User Growth Rate

Driven by new product adoption

Customer Feedback/Reviews

4.1 stars on G2

Repeat Purchase Rates

High in clinical settings

Requirements

Accurate, reliable genetic testing
Actionable, easy-to-understand reports
Seamless integration into clinical care

Why Myriad Genetics

Provide high-quality genetic insights
Educate providers on test applications
Ensure broad insurance reimbursement

Myriad Genetics Competitive Advantage

Unmatched variant classification database
Decades of trust with medical community
Broadest portfolio of specialized tests

Proof Points

Over 7 million patients tested to date
Numerous peer-reviewed publications
FDA-approved companion diagnostic tests

Myriad Genetics Market Positioning

AI-Powered Insights

Claude

Gemini

GPT

Myriad Genetics Q1 2024 Earnings Report & Press Release
Myriad Genetics Investor Relations Website (Presentations, SEC Filings)
Reputable financial news sources (e.g., Yahoo Finance, MarketWatch)
Myriad Genetics Official Company Website (myriad.com)
Competitor financial reports and websites for comparative analysis

Strategic pillars derived from our vision-focused SWOT analysis

PRECISION ONCOLOGY

Dominate testing for therapy selection.

WOMEN'S HEALTH

Lead in prenatal and hereditary cancer screens.

MENTAL HEALTH

Establish GeneSight as the standard of care.

DATA & AI

Monetize our unique dataset via AI-driven tools.

What You Do

Provides genetic tests and precision medicine.

Target Market

Patients and healthcare providers.

Differentiation

Proprietary datasets and variant classification
Established brand and physician trust

Revenue Streams

Test sales reimbursed by payers
Direct patient payments

Myriad Genetics Operations and Technology

AI-Powered Insights

Claude

Gemini

GPT

Myriad Genetics Q1 2024 Earnings Report & Press Release
Myriad Genetics Investor Relations Website (Presentations, SEC Filings)
Reputable financial news sources (e.g., Yahoo Finance, MarketWatch)
Myriad Genetics Official Company Website (myriad.com)
Competitor financial reports and websites for comparative analysis

Company Operations

Organizational Structure: Business units: Oncology, Women's Health, MH.
Supply Chain: Lab operations, sample collection kits, reagents.
Tech Patents: Portfolio of patents on genes and testing methods.
Website: https://myriad.com/

Top Clients

Board Members

Myriad Genetics Competitive Forces

Threat of New Entry

Medium: High initial capital for labs and regulatory hurdles (CLIA/CAP) are barriers, but tech advancements are lowering them.

Supplier Power

Low-Medium: Key suppliers for sequencing equipment (e.g., Illumina) have some power, but lab consumables are more commoditized.

Buyer Power

High: Large insurance payers (buyers) exert significant pressure on reimbursement rates and coverage decisions, dictating prices.

Threat of Substitution

Medium: Whole genome sequencing offers a potential future substitute, but targeted panels currently offer more actionable, cost-effective data.

Competitive Rivalry

High: Intense price competition from Natera, Invitae, and Exact Sciences. Differentiation is key to maintaining margins.

Analysis of AI Strategy

Updated: October 6, 2025 • 2025-Q4 Analysis

The Myriad Genetics AI SWOT Analysis highlights an existential opportunity. The company's crown jewel is its vast, proprietary genetic dataset—a near-insurmountable advantage if leveraged correctly. This data is the fuel for a powerful AI engine that can redefine its business. Strengths in data and expertise are robust, but weaknesses in legacy infrastructure and a potential talent gap must be addressed immediately. The opportunities are transformative: AI can slash operational costs through automation, create new predictive products, and unlock high-value pharma partnerships. However, the threat from AI-native competitors is real and urgent. Myriad must move decisively to unify its data, invest in modern ML infrastructure, and embed AI not as a project, but as the core of its scientific and operational strategy to secure its future leadership.

Natera Invitae Exact Sciences Fulgent Genetics Guardant Health

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To advance health and well-being by making genetic insights integral to every major health decision for millions.

Strengths

DATASET: 30+ years of proprietary, curated genetic data is a massive advantage
EXPERTISE: In-house bioinformatics and variant science teams are foundational
SCALE: High test volume generates continuous stream of new data for models
CHANNELS: Established clinical channels to deploy AI-driven insights
VALIDATION: Clinical validation processes can be applied to AI algorithms

Weaknesses

INFRASTRUCTURE: Legacy tech stack may not be optimized for large-scale ML ops
TALENT: Competition for top-tier AI/ML talent in healthcare is fierce
INTEGRATION: Siloed data across different business units could hinder AI
SPEED: Traditional R&D cycles may be too slow for rapid AI development
COST: Significant investment required for compute power and AI platforms

Opportunities

AUTOMATION: Use AI to automate variant classification, reducing costs and time
PREDICTION: Develop predictive models for disease risk and treatment response
INSIGHTS: Generate novel biological insights from data for pharma partners
PERSONALIZATION: AI can create hyper-personalized reports for patients/doctors
OPERATIONS: AI can optimize lab logistics, billing, and sales force efficiency

Threats

COMPETITORS: Nimbler, AI-native startups could leapfrog Myriad's capabilities
BIAS: Models trained on limited demographic data could perpetuate bias
REGULATION: Evolving FDA/global regulations for AI in diagnostics are uncertain
SECURITY: AI systems and the data they use are high-value targets for cyberattacks
EXPLAINABILITY: 'Black box' AI models may face resistance from clinicians

Key Priorities

DATA: Build a unified, AI-ready data platform across all business units
AUTOMATION: Prioritize AI for automating variant interpretation to boost margins
PRODUCTS: Launch a new AI-powered predictive risk score product within 24 months
PARTNERSHIPS: Leverage AI-generated insights to secure a major pharma partnership

Create professional SWOT analyses in minutes with our AI template. Get insights that drive real results.

Get Free SWOT Analysis Template

Myriad Genetics Financial Performance

AI-Powered Insights

Claude

Gemini

GPT

Myriad Genetics Q1 2024 Earnings Report & Press Release
Myriad Genetics Investor Relations Website (Presentations, SEC Filings)
Reputable financial news sources (e.g., Yahoo Finance, MarketWatch)
Myriad Genetics Official Company Website (myriad.com)
Competitor financial reports and websites for comparative analysis

Profit: Net Loss of ($4.8M) in Q1 2024, improving.

Market Cap: $1.9 Billion (as of mid-2024)

Stock Performance

Annual Report: Available on Myriad's Investor Relations website.

Debt: Total debt of approximately $50 million.

ROI Impact: Improved pricing and volume drive future ROI.

SWOT Index

Composite strategic assessment with 10-year outlook

/ 100

Market Leader

ICM Index

STRATEGIC ADVISOR ASSESSMENT

Myriad's societal-level ambition is backed by a solid, if challenged, market position. The OKRs directly address key weaknesses (profitability) and threats (competition), boosting achievability. A high AI leverage potential based on its unique dataset is its greatest asset. The primary constraint is the intense competition reflected in the balanced SWOT score, which tempers the growth multiplier. The path forward requires flawless execution on profitability and AI-driven differentiation to realize its potential.

SWOT Factors

Upside: 83.3 Risk: 80.0

OKR Impact

AI Leverage

Top 3 Strategic Levers

ACHIEVE PROFITABILITY: Prove the business model is sustainable.

UNLOCK DATA: Monetize the core data asset through AI/pharma.

WIN MARKETS: Accelerate MRD/liquid biopsy to capture next wave.

AI Disclosure

This report was created using the Alignment Method—our proprietary process for guiding AI to reveal how it interprets your business and industry. These insights are for informational purposes only and do not constitute financial, legal, tax, or investment advice.

Next Step

Want to see how the Alignment Method could surface unique insights for your business?

Request your custom report Contact our team

About Alignment LLC

Alignment LLC specializes in AI-powered business analysis. Through the Alignment Method, we combine advanced prompting, structured frameworks, and expert oversight to deliver actionable insights that help companies understand how AI sees their data and market position.